Close

Anti-CD44 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1086-YY)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-CD44 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • CD44
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 960
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-1086-YY 5C10 Mouse IgG2b, κ
DMAb-1076-YY 3H1355 Mouse IgG2b Recognizes an epitope encoded by exons v7-v8 on the variant portion of human CD44
DMAb-0247-CN CVS18 Mouse IgG1
DMAb-0228-CQ 156-3C11 Mouse IgG2a, κ Stimulated human leukocytes
DMAb-0230-CQ CD44v4/1219 Mouse Human IgG2a, κ Recombinant fragment corresponding to the v4 domain of human CD44
DMAb-0231-CQ CD44v4/1700R Rabbit Human IgG, κ Recombinant fragment corresponding to the v4 domain of human CD44
DMAb-0232-CQ DF1485 Mouse IgG1, κ Purified CD44 antigen (PGp-1) from lymphocyte membrane
DMAb-0233-CQ F10-44-2 Mouse Human IgG2a Purified human T cells
DMAb-0234-CQ HCAM/1097 Mouse IgG1, κ Recombinant human HCAM protein
DMAb-0235-CQ HCAM/918 Mouse IgG2a, κ Recombinant human HCAM protein
DMAb-0236-CQ Hermes-1 Rat IgG2a 80-95 kDa lymphocyte surface glycoprotein H-CAM (CD44)
DMAb-0237-CQ IM7 Rat IgG2b Dexamethasone-induced cells of the SJL mouse spontaneous myeloid leukemia M1
DMAb-0238-CQ MEM-263 Mouse IgG1 COS-7 cells, African Green Monkey (NM_000610.3)
DMAb-0239-CQ MEM-85 Mouse Human IgG2b
DMAb-0240-CQ P2A1 Mouse Human IgG2a Ocular melanoma cell line (V+B2)
DMAb-0241-CQ SPM544 Mouse IgG2a, κ Stimulated human leukocytes
DMAb-0242-CQ VFF-11 Mouse Human IgG1 Glutathione S Transferase (GST) fusion protein corresponding to the variable domains (v3 to v10) of human CD44
DMAb-0243-CQ VFF-17 Mouse Human IgG2b Made to Human CD44v7/8
DMAb-0244-CQ VFF-327 Mouse Human IgG1 Made to Human CD44v3
DMAb-0245-CQ VFF-8 Mouse Human IgG1 Made to Human CD44v5
DMAb-0246-CQ VFF-9 Mouse Human IgG1 Made to Human CD44v7
DMAb-0249-CQ DB105 Mouse IgG1
DMAb-0253-CQ BU52 Mouse Human IgG1
DMAb-0254-CQ BU75 Mouse Human IgG2a
DMAb-0255-CQ hCD44 Mouse Human IgG1
DMAb-0256-CQ Hermes-3 Mouse Human IgG2a, κ
DMAb-0257-CQ HI44a Mouse Human IgG1
DMAb-0258-CQ SPM521 Mouse Human IgG2a, κ
DMAb-0260-CQ KM201 Rat Mouse IgG
DMAb-0262-CQ NKI-P2 Mouse Human IgG1
DMAb-0264-CQ BSB-12 Mouse Human IgG2a
DMAb-0267-CQ HCM15-1 Mouse IgG1, κ Purified human protein
DMAb-0175-WJ AV6 Mouse Chicken IgG1
DMAb-0176-WJ B-F24 Mouse Human IgG1 U937 cell line
DMAb-0253-CQ BU52 Mouse Human IgG1
DMAb-0254-CQ BU75 Mouse Human IgG2a
DMAb-0230-CQ CD44v4/1219 Mouse Human IgG2a, κ Recombinant fragment corresponding to the v4 domain of human CD44 (exact sequence is proprietary)
DMAb-0231-CQ CD44v4/1700R Rabbit Human IgG, κ Recombinant fragment corresponding to the v4 domain of human CD44 (exact sequence is proprietary)
DMAb-0182-WJ CD44v9/1459 Mouse Human IgG1, κ Recombinant fragment corresponding to the v9 domain of human CD44 (exact sequence is proprietary)
DMAb-0247-CN CVS18 Mouse Equine IgG1
DMAb-0233-CQ F10-44-2 Mouse Human IgG2a CD44 antibody was raised in mouse using human CD44 as the immunogen
DMAb-0255-CQ hCD44 Mouse Human IgG1
DMAb-0236-CQ Hermes-1 Rat IgG2a 80 - 95 kDa lymphocyte surface glycoprotein H-CAM (CD44)
DMAb-0257-CQ HI44a Mouse Human IgG2a
DMAb-0237-CQ IM7 Rat IgG2b, κ
DMAb-0194-WJ IM7.8.1 Rat Mouse IgG2b CD44 (Ly 24, Pgp-1) (Mouse CD44)
DMAb-0260-CQ KM201 Rat Mouse IgG1
DMAb-0198-WJ KM81 Rat Mouse IgG2a
DMAb-0199-WJ 9A4 Rat Mouse IgG1
DMAb-0205-WJ B-R8 Mouse Human IgG1, κ U266 cell line
DMAb-0232-CQ DF1485 Mouse IgG1, κ
DMAb-0234-CQ HCAM/1097 Mouse Human IgG1, κ Recombinant human HCAM protein
DMAb-0235-CQ HCAM/918 Mouse Human IgG2a, κ Recombinant human HCAM protein
DMAb-0256-CQ Hermes-3 Mouse Human IgG2a, κ Recombinant protein corresponding to human CD44 (P16070)
DMAb-0227-WJ J-173 Mouse Human IgG1 LAZ 221 ALL
DMAb-0174-YJ 3H2606 Mouse Mouse IgG1 Spleen cells from B6PL-Ly-2a/Ly-3a B6-Ly-1a mice.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD44 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1086-YY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.